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Abstract
Hepatocyte nuclear factor 4a (HNF4a) and CCAAT/enhancer-binding protein a (C/EBPa) are important for the transcriptional
control of coagulation factors. To determine in vivo the direct role of HNF4a and C/EBPa in control of genes encoding
coagulation factors, a synthetic small interfering (si)RNA approach was used that enabled strong reduction of mouse
hepatic HNF4a and C/EBPa under conditions that minimized target-related secondary effects. For both HNF4a and C/EBPa,
intravenous injection of specific synthetic siRNAs (siHNF4a and siC/EBPa) resulted in more than 75% reduction in their liver
transcript and protein levels 2 days post-injection. For siHNF4a, this coincided with marked and significantly reduced
transcript levels of the coagulation genes Hrg, Proz, Serpina5, F11, F12, F13b, Serpinf2, F5, and F9 (in order of magnitude of
effect) as compared to levels in control siRNA injected animals. Significant decreases in HNF4a target gene mRNA levels
were also observed at 5 days post-siRNA injection, despite a limited level of HNF4a knockdown at this time point. Compared
to HNF4a, C/EBPa knockdown had a modest impact on genes encoding coagulation factors. A strong reduction in C/EBPa
transcript and protein levels resulted in significantly affected transcript levels of the control genes Pck1 and Fasn and a
modest downregulation for coagulation genes Fba, Fbg and F5. F5 and F11 were the sole coagulation genes that were
significantly affected upon prolonged (5 day) C/EBPa knockdown. We conclude that in the mouse, HNF4a has a direct and
essential regulatory role for multiple hepatic coagulation genes, while a role for C/EBPa is more restricted. In addition, this
study demonstrates that synthetic siRNA provides a simple and fast means for determining liver transcription factor
involvement in vivo.
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Introduction
Hepatocyte nuclear factor 4a (HNF4a) and CCAAT/enhancer-
binding protein a (C/EBPa) are two distinct transcription factors
that are of key importance in controlling many genes specifically
expressed in the liver and associated with a number of critical
metabolic pathways [1–3]. In addition, both transcription factors
are claimed to be critical for control of the hepatic genes encoding
proteins in the coagulation pathway. For HNF4a, first evidence
came from in vitro gene promoter studies for human coagulation
genes. Functional HNF4a binding sites were identified near the
genes encoding factor (F) II (F2), VII (F7), VIII (F8), IX (F9), X
(F10), XI (F11), XII (F12), protein S (PROS1), protein Z (PROZ)
and antithrombin III (SERPINC1) [4–13].
The in vivo importance of HNF4a in regulating hepatic
transcription of coagulation genes described in studies using
hepatocyte-specific HNF4a knockout mice [14,15]. Hnf4a disrup-
tion affected expression of factor (F) F5, F9, F11, F12, F13b,
protein C inhibitor (Serpina5), protein Z (Proz), a2-antiplasmin
(Serpinf2), protein Z inhibitor (Serpina10), and heparin Cofactor II
(Serpind1), whereas no effects were observed for F2, F7, F8, F10,
protein S (Pros1) and antithrombin (Serpinc1) [14,15]. For C/EBPa,
studies on the relevance to coagulation are limited. A recent
CHIPseq study determined the genome-wide occupancy of C/
EBPa in the livers of human, mouse, dog, opossum, and chicken.
Fibrinogen A (FGA) and F2 were identified among 32 genes
located near 35 C/EBPa binding events that were conserved
among these five vertebrates [16]. In the mouse genome, Fga and
F2, C/EBPa binding sites were 45 and 64 bp from the
transcription start site, respectively. However, it should be
emphasized that binding does not necessarily correlate with
functional activity in controlling gene transcription. Furthermore,
carriers of hemophilia B Leiden have a causal mutation in a C/
EBPa binding site in F9 promoter [17], and in line, liver-specific
C/EBPa-null mice display reduced hepatic expression of F9
[17,18]. Finally, in vitro studies demonstrated requirement of C/
EBPa for F8 expression, but this involved nonhepatic inflamed
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F9 and F8 are regulated by C/EBPa is unknown.
The study of the in vivo roles of HNF4a and C/EBPa in control
of gene transcription in liver employed a conditional gene
knockout approach because conventional gene knockouts for
HNF4a and C/EBPa were embryonic lethal [20,21]. In general, a
conditional gene knockout approach does not allow a rapid
significant deletion of the gene of interest in vivo without
challenging liver physiology; fast adenovirus-mediated hepatic
delivery of the required Cre- recombinase does allow rapid hepatic
disruption of ‘floxed’ alleles but is concomitant with adenovirus-
related acute hepatic inflammation [22,23]. Similarly, inducible
liver-specific gene disruption based on the MX1-Cre transgene
requires a burst of circulating interferon to evoke the necessary
activation of MX1-Cre [24]. Meaningful studies of the role of
hepatic transcription factors can therefore only start after weaning
of the adenovirus or interferon effects. At that time, transcription
factor deletion may already have induced (secondary) changes in
liver physiology and compensatory changes in expression of other
hepatic transcription factors. It may lead to a possible misinter-
pretation of the direct role of a given transcription factor in gene
regulation. Hence, the current observations regarding the role of
HNF4a and C/EBPa in regulating coagulation gene transcription
obtained in adult mice lacking HNF4a and C/EBPa from birth on
(Cre recombinase under control of the albumin promoter) [25],
following Cre supplied by means of adenovirus [26] or the MX1-
Cre transgene [27] may be in part secondary to changes in liver
physiology and changes in expression of other hepatic transcrip-
tion factors. This may, explain the unexpected transcriptional
increase of numerous hepatically expressed genes including the
coagulation gene Serpind1 and absence of effects for the in vitro
identified targets F2, F7, F8, F10, Pros1 and Serpinc1 in livers from
mice lacking HNF4a from birth [14,15].
Recently, lipid-based reagents became available that allow
efficient delivery of synthetic small interfering (si) RNAs to livers of
adult mice following systemic injection [28]. Thus, transient
knockdown of target gene expression can be achieved rapidly
(within two days post siRNA delivery) and does not involve
changes in liver physiology as a result of harsh methodology. In the
present study, we used this in vivo siRNA approach to rapidly
reduce HNF4a and C/EBPa expression in mouse livers and to
determine the impact of these two distinct transcription factors on
hepatic coagulation gene transcription.
Materials and Methods
siRNA screening and validation
Pre-designed siRNAs for mouse HNF4a and C/EBPa mRNAs
were purchased from Ambion Applied Biosystems, Carlsbad,
California, USA (Ambion SilencerH Pre-designed for HNF4a;
catalogue numbers 67633 (#1), 67634 (#2) and 67635 (#3) with
sense sequences GGC AGA UGA UCG AAC AGA UUU, CCA
AUG UCA UUG UUG CUA AUU, and AGA GGU CCA UGG
UGU UUA AUU, respectively and for mouse C/EBPa; catalogue
numbers 63853 (#1), 63854 (#2), 63855 (#3) with sense
sequences GCA AAA AUG UGC CUU GAU AUU, AAA
GCU GAG UUG UGA GUU AUU, and ACU CAA AAC UCG
CUC CUU UUU, respectively). Ambion’s siNEG (catalogue
number 4404020) was used as control siRNA. This negative
control siRNA was selected using a modified blast to account for
short sequence length and demonstrated to exclude significant
homology to any known gene targets in RefSeq and MirBase
(more detailed documentation on this negative control siRNA is
available on the manufacturer’s website [29]). Hepatocytes from
female C57Black6/J mice (Charles River, Maastricht, The
Netherlands) were isolated through retrograde collagenase perfu-
sion and cultured in collagen-coated dishes exactly as previously
described [30]. Twenty four hours after isolation 10
6 cells were
transfected with the siRNA (final concentration 0.3, 3 or 30 nM)
using the Dharmafect Duo transfection reagentH (Dharmacon, T-
2010-03) according to the manufacturer’s protocol. Twenty-four
hours after transfection, levels of HNF4a and C/EBPa mRNAs
were determined by quantitative real-time PCR (see below).
Sequences from siRNAs yielding maximal reduction of transcript
levels at a siRNA concentration of 3 nM were considered for use
in in vivo studies.
Gene knockdown in mouse liver
Control siNEG, siHNF4a and siC/EBPa (Ambion In-Vivo-
Ready for catalogue numbers 4404020, 67633 and 63855,
respectively) were complexed with InvivofectamineH 2.0 Reagent
(Invitrogen, Life technologies Corporation, USA) exactly accord-
ing to the manufacturer’s protocol. Subsequently, female
C57Black/6J mice (weighing 17–19 gram) were intravenously
injected via the tail vein with 200 ml complexed siRNA at a dose of
approximately 7 mg of siRNA per kg body weight (in total 54
animals, 18 animals per siRNA). At two and five days post siRNA
injection, animals (9 mice per siRNA for each time point) were
anesthetized by a subcutaneous injection with a mixture of
ketamine (100 mg/kg), xylazine (12.5 mg/kg) and atropine
(125 mg/kg) after which the abdomen was opened by a midline
incision and a blood sample on sodium citrate (final concentration
0.32%) was drawn from the inferior caval vein. Plasma was
obtained by centrifugation and stored at 280uC until use. Liver
was isolated and weighed, and liver left lobule was snap-frozen for
mRNA and protein analyses and stored at 280uC until use. All
mice were housed under a 12-h light/dark cycle, with standard
chow diet and drinking water provided ad libitum. All experi-
mental procedures were approved by the animal welfare
committee of the Leiden University (under registration # 11005).
For HNF4a, as a reference, liver materials from 45-day old
female HNF4a-null mice with a liver-specific deletion of exons 4
and 5 of the Hnf4a gene (HNF4a-floxed/floxed with albumin-Cre;
KO) or control mice (HNF4a-floxed/floxed without albumin-Cre;
FLOX) [25] were used.
RNA isolation and real-time RT-PCR
Liver samples (20–30 mg) were homogenized in RNAzol (Tel-
Test) and RNA isolation and cDNA synthesis was performed as
previously described [31]. Gene-specific quantitative real-time
PCR (QPCR) primers for Pck1, Fasn, Scd1, Lgp and Gys2 have been
described previously [32]; all other gene specific QPCR primers
were designed with the Primer Express software (Applied
Biosystems). QPCR primer sequences are presented in Table 1.
QPCR was performed on the ABI Prism 7900 HT Fast Real-Time
PCR System from Applied Biosystems and data were analysed
using the accompanying Sequence Detection System software.
The comparative threshold cycle method with b-actin as internal
control was used for quantification and normalization. siNEG-
injected animals were set as a reference and the DCt values of the
individual samples were related to the mean DCt of the reference
group.
Immunoblotting
Frozen liver material (10–20 mg) was grounded, liver protein
(15 mg) was denatured, separated on 8–10% NovexH Tri-Glycine
gels, and immunoblotted using a goat polyclonal IgG against
human HNF4a (sc-6556, Santa Cruz Biotechnology) or rabbit
HNF4a and C/EBPa Control of Coagulation Genes
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ß-actin was detected using rabbit polyclonal against human ß-actin
(Ab8227, Abcam) and served as protein loading control. The
antibodies are reactive to mouse HNF4a, C/EBPa (both p42 and
p30 unit) and ß-actin, respectively. Bound IgG was detected using
horseradish peroxidase-labeled anti-goat (sc-2020, Santa Cruz) or
anti-rabbit (172-1019, Bio Rad) IgG followed by enhanced
chemiluminescence system (Amersham Pharmacia Biotech) to
detect peroxidase activity.
Plasma analyses
Plasma alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), alkaline phosphatase (ALP) and bilirubin (total and
conjugated) levels were determined using routine clinical chem-
istry assays. Global coagulability of the plasma was determined by
measuring the prothrombin time (PT, Simple Simon PT system,
Zafena), and the activated partial thromboplastin time (APTT) by
using the STA Neoplastin Plus reagent (Roche) on the STart 4
analyzer (Diagnostica Stago). Plasma F5 activity was analyzed by
using chromogenic substrate conversion [33] and activity levels of
factor (F) F11 and F12 were measured with APTT-based assays
[31]. Plasma fibrinogen antigen levels were assessed with a
commercial murine ELISA kit from Affinity Biologicals. In plasma
assays of individual coagulation factors, pooled normal mouse
plasma was used to generate standard curves and the control
siNEG-injected group was set as a reference (100%).
Statistical analyses
Data were analysed with the GraphPad Instat software.
Statistical differences between control siNEG and siHNF4a or
Table 1. QPCR primer sequences.
Gene Forward primer (59-3 9) Reverse primer (59-3 9)
Actb AGGTCATCACTATTGGCAACGA CCAAGAAGGAAGGCTGGAAAA
Apoc2 AAGATGACTCGGGCAGCCT CAGAGGTCCAGTAACTTAAGAGGGA
Apoa4 CAGCTGACCCCATACATCCAG TCATCGAGGTGTGCAGGTTG
Cd36 GTTCTTCCAGCCAATGCCTTT ATGTCTAGCACACCATAAGATGTACAGTT
Cebpa ATAGACATCAGCGCCTACATCGA GTCGGCTGTGCTGGAAGAG
Cebpb CGGGACTGACGCAACACA CCGCAGGAACATCTTTAAGTGATTA
Cyp4v3 CTCTCCGAGTTTTCCCATCTGT TTGTAACCGCCCACTTCACA
F2 GGACGCTGAGAAGGGTATCG CCCCACACAGCAGCTCTTG
F5 CATGGAAACCTTACCGACAGAAA CATGTGCCCCTTGGTATTGC
F7 CGTCTGCTTCTGCCTCTTAGA ATTTGCACAGATCAGCTGCTCAT
F9 GCAAAACCGGGTCAAATCC ACCTCCACAGAATGCCTCAATT
F10 GTGGCCGGGAATGCAA AACCCTTCATTGTCTTCGTTAATGA
F11 GAAGGATACGTGCAAGGGAGATT CAAGTGCCAGACCCCATTGT
F12 GGGCTTCTCCTCCATCACCTA GCAACTGTTGGTTTTGCTTTCC
F13a1 GATGTCCTGGCCAAACAAAG GGCAGCACCTCGGACCTT
F13b GACACTGCCCCCTGAGTGTGTTGAAA AACAACCACACCGTTTGCTATG
Fasn CCCTTGATGAAGAGGGATCA ACTCCACAGGTGGGAACAAG
Fga TTCTGCTCTGATGATGACTGGAA GGCTTCGTCAATCAACCCTTT
Fgg TGCTGCCTGCTTTTACTGTTCTC TCTAGGATGCAACAGTTATCTCTGGTA
Gys2 GACACTGAGCAGGGCTTTTC GGGCCTGGGATACTTAAAGC
Hnf4a AGAGGTTCTGTCCCAGCAGATC CGTCTGTGATGTTGGCAATC
Hrg AAAACGGATAATGGTGACTTTGC TCCCCTCCTCTCGCTCTTATAA
Lgp CCAGAGTGCTCTACCCCAAT CCACAAAGTACTCCTGTTTCAGC
Pck1 CTGGCACCTCAGTGAAGACA TCGATGCCTTCCCAGTAAAC
Plg TGACATTGCCCTGCTGGAAAC CAGACAAGCTGGAATGACTTTATCC
Proc GCGTGGAGGGCACCAA CCCTGCGTCGCAGATCAT
Pros1 GGTGGCATCCCAGATATTTCC CACTTCCATGCAGCCACTGT
Proz GCAGCCAGAGTCAGCCTAGCT CACGCCGGCACAGAAGTC
Scarb1 GCCAGGAGAAATGCTTTTTGTT GGCCTGAATGGCCTCCTTA
Scd1 AGCTGGTGATGTTCCAGAGG GTGGGCAGGATGAAGCAC
Serpina5 TCTGGCATTACTGACCATACCAA GACTCTTCAACCTCCATCATGGA
Serpina10 TGGCCCTGGAGGACTACTTG CCATTTTCCTGGTTTTCATATTCTG
Serpinc1 TGGGCCTCATTGATCTCTTCA CCTGCCTCCAGCAACGAT
Serpind1 GAATGGCAATATGTCAGGCATCT CACTGTGATGGTACTTTGGTGCTT
Serpinf2 TTCTCCTCAACGCCATCCA GGTGAGGCTCGGGTCAAAC
doi:10.1371/journal.pone.0038104.t001
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sum test (animal studies) or Student’s t-test (hepatocyte studies). A
P-value of ,0.05 was considered to be statistically significant.
Results
siRNA screening and validation
To select an effective siRNA, mouse primary hepatocytes were
transfected with three different predesigned synthetic siRNAs for
HNF4a, and C/EBPa mRNAs. For HNF4a, all three siRNAs
were highly and equally effective with over 95% reduction of
Hnf4a transcript levels at a final concentration of 30 nM
(Figure 1A). siRNA duplex #3 had the highest level of knockdown
of Hnf4a transcript levels at the 3 nM concentration and was
selected for use in in vivo experiments. For C/EBPa, all three
siRNAs tested were highly effective, albeit that the levels of
reduction (,80%, Figure 1B) were somewhat lower as compared
to the siRNAs for HNF4a. For C/EBPa siRNA duplex #1 was
selected, being the most effective at 3 nM. The siHNF4a #3, siC/
EBPa #1 and the siNEG were subjected to large-scale preparation
in the lipid-based in vivo transfection reagent optimized for hepatic
delivery, and injected intravenously into C57Black/6J female
mice. Two days after injection, siHNF4a and siC/EBPa produced
a more than 75% reduction in liver Hnf4a and Cebpa transcript
levels (Figure 2A and 2B, respectively), as well as strongly reduced
liver HNF4a and C/EBPa protein levels (Figure 2C). For siC/
EBPa this strong level of knockdown of liver C/EBPa mRNA and
protein persisted for at least five days (Figure 2B and 2D). For
siHNF4a, HNF4a mRNA and protein levels remained reduced at
five days, but, as quantified for the transcript, only at a mean level
of 36% (Figure 2A and 2D). This relatively quick return to normal
HNF4a levels for siHNF4a was also observed in a second
independent experiment and could not be overcome by a repeat
intravenous siHNF4a injection (7 mg/kg) at day 2 after the first
injection (data not shown).
During the 5-day observation period siHNF4a and siC/EBPa
did not affect mouse body weight and liver weight as compared to
siNEG injected animals or uninjected controls. Gross pathological
analysis revealed no abnormalities. Plasma bilirubin, ALT, AST
and ALP in siNEG injected animals were comparable to those
observed for uninjected controls (Table 2) as expected [28]. As
compared to the siNEG injected controls, at two days post siRNA
injection, ALP levels were significantly increased by siHNF4a, and
at 2 days significantly reduced by siC/EBPa. At 2 and 5 days,
plasma bilirubin, AST, ALT levels in siHNF4a and siC/EBPa
were below the limits of detection and comparable to siNEG
injected animals.
Changes in transcription of control genes following liver
HNF4a and C/EBPa knockdown
In livers of 6-wk-old liver-specific HNF4a deficient animals [25]
apolipoprotein C2 (Apoc2), apolipoprotein A4 (Apoa4), and
cytochrome P450 family member 4v3 (Cyp4v3) are among the
genes that are highly expressed in the liver and are strongly down-
regulated by prolonged HNF4a ablation, whereas in these mice
scavenger receptor B1 (Scarb1) and CD36 (Cd36) are among the
genes that are strongly upregulated [25,34] (Figure 3B). The
upregulation is suspected to be secondary and may result of
prolonged hepatic HNF4a ablation. In livers of mice two days post
siHNF4a injection, like in livers of liver-specific HNF4a deficient
mice, strongly reduced Apoc2, Apoa4 and Cyp4v3 transcript levels
were observed (Figure 4A). Also at five days, Apoc2, Apoa4, and
Cyp4v3 remained significantly reduced in siHNF4a compared to
the siNEG injected animals, despite the limited level of HNF4a
knockdown at this time point (Figure 4C and 2A). Scarb1 and Cd36
transcript levels were not affected by siHNF4a injection at two or
five days (Figure 4A and 4C). Mice in which hepatic C/EBPa has
been targeted by recombinant adenovirus encoding siRNA against
C/EBPa mRNA demonstrated a role in (fasted) liver glucose and
fat metabolism by affecting amongst others transcription of
phosphoenolpyruvate carboxykinase (Pck1), glycogen synthase
(Gys2), fatty acid synthase (Fasn), stearoyl-CoA-desaturase 1 (Scd1)
and liver glycogen phophatase (Lgp) [32]. As demonstrated in
Figure 4B, two days post siC/EBPa injection, the livers of (non-
fasted) mice displayed significant changes in transcript levels of
Pck1 and Fasn, Scd1 displayed a 40% non-significant decrease,
whereas Gys2 and Lgp were unaffected as compared to siNEG
injected animals. As in C/EBPa knockouts [35], siC/EBPa
Figure 1. Screening and validation of siRNAs in mouse primary hepatocytes. Screening of siRNA in mouse primary hepatocytes 24 hours
after transfection with 0.3, 3 and 30nM of three Hnf4a-specific (#1–3, panel A), three Cebpa -specific siRNAs (#1–3, panel B) or a control siRNA (siNEG,
panel A and B, open bars). Hnf4a and Cebpa transcript levels were determined by quantitative real-time PCR. b-actin was used as internal control for
quantification and normalization. The DCt values of the individual samples were related to the mean DCt of the reference group (siNEG). On the x-axis
siRNA concentrations are indicated. Data are expressed as mean with error bars representing the difference between 2 POWER of upper and lower
range of the mean DDCt (difference 2‘DDCt+SEM and 2‘DDCt2SEM). Individual experiments were performed in triplicate. Data were statistically
analyzed using the Student’s t-test. P-values ,0.05 were regarded as statistically significant. *P,0.05, **P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0038104.g001
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Cebpb (+73%, Figure 5) which is considered a compensatory
response to C/EBPa knockdown [35]. Cebpb, Pck1, Fasn and Scd1
transcript levels in siC/EBPa-injected mice were comparable to
levels in siNEG animals at five days after injection, despite the
persistent strong level of knockdown (Figure 2B and 4D).
Changes in liver coagulation gene transcription following
HNF4a and C/EBPa knockdown
Livers of siHNF4a injected animals with strong reduction in
HNF4a transcript and protein levels (two days) displayed markedly
and significantly reduced transcript levels of Hrg (297%), Proz
(270%), Serpina5 (262%), F11 (250%), F12 (246%), F13b
(241%), Serpinf2 (236%), F5 (238%), F9 (227%) (Figure 6A).
For the other coagulation genes that were analysed (Figure 3A) we
did not observe significant changes as compared to siNEG injected
animals. At five days, transcript levels of Hrg, Proz, Serpina5, F11
and F12 (273%, 224%, 279%, 226%, and 227%, respectively)
remained reduced, despite the limited level of HNF4a knockdown
at this time point (Figure 2A, 6C). Interestingly, at five days,
significant elevations in transcript levels of Serpinf2, Serpind1 and
Pros1 (+20%, + 22%, +32%, respectively) were observed
(Figure 6C). Overall, the HNF4a-mediated downregulation of
coagulation gene transcript levels in livers of siHNF4a injected
animals seemed to largely reproduce those observed in 6 week old
HNF4a-null mice with prolonged HNF4a ablation in the liver
from birth on (compare Figure 3A, 3B), albeit at a lower extent
and, importantly, with two-day siHNF4a injected animals not
showing any upregulating effects.
Figure 2. Knockdown of HNF4a and C/EBPa in mouse liver. The selected siHNF4a-specific siRNA #3 (67635), siC/EBPa-specific siRNA #1
(63853) and a control siNEG were subjected to large-scale preparation in the lipid-based in vivo transfection reagent optimized for hepatic delivery
and intravenously injected in C57Black/6J mice (7 mg siRNA per kg mouse, injection volume 200 ml, 18 animals per siRNA). At two and five days post
siRNA injection, mice (n=9 per siRNA for both time points) were sacrificed and livers were subjected to HNF4a (panel A) or C/EBPa (panel B)
transcript analysis by QPCR. b-actin was used as internal control for quantification and normalization. The DCt values of the individual samples were
related to the mean DCt of the reference group (siNEG). Data are expressed as mean with error bars representing the difference between 2 POWER of
upper and lower range of the mean DDCt (see figure 1 legends). Data were statistically analysed using Mann Whitney Rank Sum test. P-values,0.05
were regarded as statistically significant. ***P,0.001. In addition, immunoblotting for HNF4a and C/EBPa was performed for liver homogenates that
were prepared for three randomly selected mice per siRNA for both two days (panel C) and five days post injection (panel D). The C/EBPa antibody
used, reacts with both C/EBPa p42 and p30.
doi:10.1371/journal.pone.0038104.g002
Table 2. Plasma analysis of siHNF4a and siC/EPBa injected
mice.
2 days post siRNA
injection 5 days post siRNA injection
siNEG siHNF4a siC/EPBa siNEG siHNF4a siC/EPBa
PT (sec) 11.460.1 11.460.2 11.660.1 12.260.1 11.860.1* 12.560.1*
aPTT (sec) 28.260.6 28.660.8 27.860.4 31.060.4 31.960.7 30.660.6
F5 (%) 100678 0 611 9065 10067 126668 3 65
F11 (%) 100668 0 64* N.D. 100659 0 68 N.D.
F12 (%) 10062 10062 N.D. 100648 5 68 N.D.
Fbg (%) 100659 8 637 2 62** 100610 121687 0 63**
Tbil (mmol/L) 8.760.7 8.560.2 8.460.4 8.660.3 9.060.2 8.660.4
ALT (U/L) ,20 ,20 ,20 ,20 ,20 ,20
AST (U/L) 43683 1 643 2 623 4 634 0 643 9 65
ALP (U/L) 12068 18165** 9864* 90611 107676 9 64
Data are represented as mean 6 SEM with the group injected with negative
siRNA set as a reference.
*P,0.05 and
**P,0.01 versus mice injected with control siNEG. Prothrombine time (PT),
activated partial thromboplastine time (aPTT), Factor activity (F11), Factor 12
activity (F12), Fibrinogen antigen (Fbg) and circulating liver enzymes alanine
transaminase (ALT), aspartate aminotransferase (AST), alkaline phosfatase (ALP)
and plasma total billirubine (Tbil). N.D.=not determined. Values for uninjected
control mice: billirubin 8.360.2 mmol/L, ALT,20 U/L, AST 2863 U/L, ALP
9666 U/L.
doi:10.1371/journal.pone.0038104.t002
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impact on coagulation gene transcription. Strong reduction in C/
EBPa transcript and protein levels resulted in small though
significantly reduced transcript levels of fibrinogen a and c (Fga
and Fgg 225% and 224%, respectively) and F5 (227%) at two
days post siC/EBPa injection. Only, the reduction in F5 transcript
levels persisted upon prolonged C/EBPa knockdown (231%). At
this time point also F11 transcript levels became significantly
reduced (221%). For the many other coagulation genes that were
analyzed, neither at two (Figure 5) nor at five days (data not
shown) post siC/EBPa injection, we observed changes as
compared to siNEG injected animals that reached statistical
significance.
At two days, plasma from siHNF4a and siC/EBPa injected
animals had an APTT and PT comparable to siNEG injected
animals (Table 2). Although analyzed for only a limited number of
individual coagulation factors, at this time point, HNF4a
knockdown coincided with a significant reduction in plasma F11
activity levels, but not F12 activity levels. C/EBPa knockdown
coincided with significant reduction of plasma fibrinogen antigen
but not F5 activity levels. At five days, siHNF4a injected animals
displayed a minimal but significant shortening of the PT, while
that of siC/EBPa injected animals was minimally but significantly
prolonged. Plasma fibrinogen antigen levels remained reduced
upon prolonged C/EBPa knockdown.
Discussion
In the present study we used an in vivo synthetic small interfering
RNA approach to determine in mice the direct role of the liver
transcription factors hepatocyte nuclear factor 4a (HNF4a) and
CCAAT/enhancer-binding protein a (C/EBPa) in coagulation
gene transcription under conditions minimizing methodology or
target-related secondary effects. Shortly (two days) post intrave-
nous siHNF4a injection, we observed (strong) reductions in
transcript levels of the Hrg, Proz, Serpina5, F11, F12, F13b, Serpinf2,
F5, and F9 genes indicating that these coagulation genes are under
direct regulatory control of HNF4a. The relatively modest but fast
reduction in transcript levels of Fga, Fgg and F5 observed two days
Figure 3. Comparison of gene transcript levels in mouse livers following HNF4a knockdown and liver-specific targeted deletion of
Hnf4a. Livers from siHNF4a injected animals (panel A, black bars) and siNEG injected animals as controls (panel A, open bars) were subjected to
control and coagulation gene transcript levels by QPCR. In panel B, coagulation transcript analysis for liver materials from HNF4a-null mice (KO) or
control mice (FLOX) is included for comparison [25]. Data are presented for mice two days post siRNA injection or app. 6 weeks gene ablation (i.e. 6
weeks old HNF4a-null mice). b-actin was used as internal control for quantification and normalization. The DCt values of the individual samples were
related to the mean DCt of the siNEG or FLOX control group. Data are expressed as mean with error bars representing the difference between 2
POWER of upper and lower range of the mean DDCt (see figure 1 legends). Data were statistically analysed using Mann Whitney Rank Sum test. P-
values,0.05 were regarded as statistically significant. *P,0.05, **P,0.01, ***P,0.001. On the x-axis the coagulation genes are ranked according to
the magnitude of effects observed in the siRNA injected animals.
doi:10.1371/journal.pone.0038104.g003
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for direct regulatory control by C/EBPa. However, siC/EBPa
injection also rapidly induced increased C/EBPb transcription,
indicating a rapid onset of C/EBPa-related secondary (compen-
satory) effects and therefore we cannot exclude an underestimation
of C/EBPa’s direct role in coagulation gene transcription. Overall,
we conclude that in the mouse, HNF4a has a direct and essential
regulatory role for multiple hepatic coagulation genes. For C/
EBPa, such a role is more restricted, but may be underestimated
as result of an unexpectedly fast compensatory upregulation of
Cebpb transcription.
Analyzing the impact of liver HNF4a deficiency on a genome-
wide scale using microarrays identified an estimated 20% of the
hepatically expressed genes affected by HNF4a deficiency to be
upregulated [32,34]. Scarb1 and Cd36 were among the genes that
were strongly upregulated in liver-specific HNF4a deficient mice
while unaffected upon acute siRNA-mediated HNF4a knockdown
in mice. It was speculated that Scarb1 increase may be a secondary
consequence of altered lipid homeostasis (e.g., due to changes in
intracellular lipid levels in liver of HNF4a-null mice) [25]. A
similar mechanism may account for Cd36 albeit that this gene is
predominantly in the liver Kupffer cells. The absence of any
statistically significant upregulating effects regarding transcription
in livers of mice two days post siHNF4a injection, including Scarb1
and Cd36, suggests that at least a large portion of the upregulating
effects observed in the liver-specific knockouts are secondary to
prolonged HNF4a disruption. This supports the use of our siRNA
approach for in vivo studies on the regulating role of liver
transcription factors. In this light, it is worthwhile to denote that
prolonged knockdown i.e. 5 days post siHNF4a, despite a limited
efficacy of hepatic HNF4a knockdown (Figure 2A and 2D),
resulted in likely secondary upregulating effects for a number of
the coagulation genes (Serpinf2, Serpind1, Pros1, Figure 6C).
In the present study, C/EBPa was selected as the second liver
transcription factor in this first synthetic siRNA study on
transcriptional control of liver coagulation genes given the
observations from a recent CHIPseq study on the genome-wide
occupancy of C/EBPa in livers of multiple species [16]. In this
study, fibrinogen A (FGA) and prothrombin (F2) were among the
few genes (from a total of 32 in mouse genome) that were located
near ultraconserved C/EBPa binding regions. Indeed, in our
mouse study we identified Fga as one of the few genes likely to be
under direct transcriptional control of C/EBPa. However, F2 was
clearly not affected following siC/EBPa, suggesting that the C/
EBPa binding site located 64 bp from the transcription start site in
the mouse F2 promoter is not critical for physiological control of
F2 transcription. In addition, we were surprised not to find an
effect of siC/EBPa on mouse hepatic F9 transcription. In humans,
carriers of hemophilia B Leiden have a causal mutation in a C/
EBPa binding site in F9 promoter [17], and in line, mice with
prolonged C/EBPa ablation the liver display reduced hepatic
expression of F9 [18]. Possibly, C/EBPa interaction with the F9
promoter, and also that of F2, is of high affinity, requiring only
limited levels of C/EBPa binding to drive transcription. Despite
the strong level C/EBPa reduction of transcript (292% and
287% at 2 and 5 days respectively) and protein levels (Figure 2B
and 2D) by our synthetic siRNA approach this may not be
sufficient to unmask a role for C/EBPa for these type of targets.
Alternatively, the observed unexpectedly rapid upregulation of C/
EBPb transcript following siC/EBPa injection, may functionally
replace C/EBPa in liver [36]. Indeed, C/EBPb has been shown to
compensate for loss of C/EBPa in the regulation of Pck1 gene
expression [37]. Thus, provided the C/EBPb transcript rapidly
translates to protein (which we did not determine) a compensation
for loss of C/EBPa by C/EBPb cannot be excluded and may
explain the absence of effects of siC/EBPa on F2 and F9 and
possibly other genes.
The in vivo siRNA delivery procedure used had low toxicity
without effects on circulating liver enzymes tested (Table 2) as
expected [28]). However, as compared to the control siRNA, both
siHNF4a and siC/EBPa had a mild transient effect on serum
alkaline phosphatase levels, the circulating marker for biliary
obstruction. This suggests the presence of target-related (mild)
hepatotoxic effects. Alternatively, changing in ALP levels may
reflect a specific transcriptional regulatory role of HNF4a and C/
EBPa for genes involved in regulation of bile acid biosynthesis, as
has been reported for HNF4a [25]. In the present study, whether
siHNF4a or C/EBPa had an immediate effect on bile acid
biosynthesis genes like Cyp7a1, Cyp27a1 and Cyp8b1 was not
investigated.
Negative control siRNAs - siRNAs with sequences that do not
target any gene products - are essential to control for the effects of
siRNA delivery, and to determine whether an siRNA is considered
Figure 4. Hepatic transcription of control genes following
HNF4a and C/EBPa knockdown. At two (upper panels) and five days
(lower panels) post siRNA injection, mouse livers were subjected to
transcript levels by QPCR for a panel of control genes. Data are
presented for siHNF4a (panel A and C, black bars) and siCEBPa (panel B
and D, hatched bars) with siNEG injected animals as controls (panel A, B,
C and D, open bars). b-actin was used as internal control for
quantification and normalization. The DCt values of the individual
samples were related to the mean DCt of the siNEG group. Data are
expressed as mean with error bars representing the difference between
2 POWER of upper and lower range of the mean DDCt (see figure 1
legends). Data and were statistically analysed using Mann Whitney Rank
Sum test. P-values,0.05 were regarded as statistically significant.
*P,0.05, ***P,0.001.
doi:10.1371/journal.pone.0038104.g004
HNF4a and C/EBPa Control of Coagulation Genes
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38104Figure 6. Hepatic coagulation gene transcription following HNF4a and C/EBPa knockdown. At two (upper panels) and five days (lower
panels) post siRNA injection, mouse livers were subjected to coagulation gene transcript levels by QPCR. Data are presented for siHNF4a (panel A and
C, black bars) and siCEBPa (panel B and D, hatched bars) with siNEG injected animals as controls (panel A, B, C and D, open bars). b-actin was used as
internal control for quantification and normalization. The DCt values of the individual samples were related to the mean DCt of the siNEG group. Data
are expressed as mean with error bars representing the difference between 2 POWER of upper and lower range of the mean DDCt (see figure 1
legends). Data were statistically analysed using Mann Whitney Rank Sum test. P-values,0.05 were regarded as statistically significant. *P,0.05,
**P,0.01, ***P,0.001. Only those coagulation genes are presented for which transcript levels were significantly affected by siHNF4a or siC/EBPa (in
two or five days study group). On the x-axis the coagulation genes are ranked according to the magnitude of effects observed in the two day groups.
doi:10.1371/journal.pone.0038104.g006
Figure 5. Overview of gene transcript levels in mouse livers following C/EBPa knockdown. Livers from siCEBPa injected animals (hatched
bars) and siNEG injected animals as controls (open bars) were subjected to control and coagulation gene transcript levels by QPCR. Data are
presented for mice two days post siRNA injection. b-actin was used as internal control for quantification and normalization. The DCt values of the
individual samples were related to the mean DCt of the siNEG group. Data are expressed as mean with error bars representing the difference
between 2 POWER of upper and lower range of the mean DDCt (see figure 1 legends). Data were statistically analysed using Mann Whitney Rank Sum
test. P-values,0.05 were regarded as statistically significant. *P,0.05, **P,0.01, ***P,0.001. On the x-axis the coagulation genes are ranked
according to the magnitude of effects observed in the siRNA injected animals.
doi:10.1371/journal.pone.0038104.g005
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In our animal studies, we included a commercially available
negative control siRNA that was designed to have no significant
sequence similarity to mouse, rat, or human transcript sequences
(for description see methods and [29]). This negative control
siRNA incorporates the same chemical modifications and is
purified to the same rigorous specifications as the target-specific
siRNAs (siHNF4a and siCEBPa). In addition, this negative control
siRNA virtually lacked effects on gene transcription as determined
for multiple cell lines following exposure of relatively high doses of
negative control siRNA and analyzed by whole genome expression
arrays. Despite the careful design of the negative control, we
cannot exclude that in our experiments the control siRNA itself
had influence on our genes of interest, and thereby leading to
misinterpretation of the findings. To fully exclude such misinter-
pretation, in vivo experiments should be expanded with multiple
carefully designed negative and multiple target specific siRNA.
The HNF4a-mediated (downregulatory) changes in control and
coagulation genes in livers of siHNF4a injected animals largely
reproduced that of 45-day-old HNF4a-null mice and wild-type
mouse primary hepatocytes rapidly after siRNA-mediated HNF4a
knockdown, indicating that the single negative control siRNA
approach used in the present study allowed reliable estimation of
the (direct) effects of siHNF4a and also that of siC/EBPa.
In vitro siRNA screening and validation in (primary) mouse
hepatocytes showed that the siRNAs targeting HNF4a had higher
efficacy than those targeting C/EBPa (Figure 1). Remarkably, in
vivo we observed the opposite i.e. the siC/EBPa were more
effective than siHNF4a (Figure 2). Both HNF4a and C/EBPa
displayed normal and stable expression in primary mouse liver
cells i.e Ct comparable to fresh livers. This suggests that the
discrepancy between the in vitro and in vivo findings could not be
attributed to a rapid decline in HNF4a in vitro and thereby the
efficacy of the siHNF4a is over estimated. Whether the difference
in efficacy is due to differences in in vivo siRNA delivery, processing
and or stability of the siRNA is unknown. However, it emphasizes
that the in vitro experiments (as performed) are useful for
identifying siRNAs with in vivo potential, but are not fully
predictive for identifying most effective siRNA for in vivo use.
Although, these aspects of in vivo siRNA approach should be
improved, this study demonstrates that synthetic siRNA provides a
simple and fast means for determining direct transcription factor
involvement in vivo under conditions minimizing secondary effects.
Here, in vivo siRNA-mediated knockdown enabled us to establish
the direct contribution of HNF4a and C/EBPa to the regulation
of coagulation gene transcription.
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